دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Inside Front Cover
Jiao'e Zeng MD, Shenglian Gan MMed, Nianrong Mi MMed, Yunfeng Liu MD, Xiaofei Su MD, Wenli Zhang MMed, Juan Zhang MMed, Fang Yu MMed, Xiaolin Dong MD, Minmin Han MMed, Jianfeng Luo PhD, Yi Zhang MD, Li Chen PhD, Jianhua Ma MD,Â
doi : 10.1111/dom.15285
Back Cover
Peter Rossing MD, Stefan D. Anker MD, Gerasimos Filippatos MD, Bertram Pitt MD, Luis M. Ruilope MD, Liana K. Billings MD, Jennifer B. Green MD, Daisuke Koya MD, Ofri Mosenzon MD, Kevin M. Pantalone DO, Christiane Ahlers PhD, Andrea Lage MD, Robert Lawatscheck MD, Andrea Scalise MD, George L. Bakris MD,Â
doi : 10.1111/dom.15286
Therapeutic carbohydrate restriction and sodium-glucose transporter 2 inhibitors in chronic kidney disease: A potentially powerful combination
Karen M. Dwyer MBBS, Penny Figtree MBBS, Alok Gupta MBBS,Â
doi : 10.1111/dom.15195
Management of the ‘wicked’ combination of heart failure and chronic kidney disease in the patient with diabetes
David S. H. Bell MB, Janet B. McGill MD, Terri Jerkins MD,Â
doi : 10.1111/dom.15181
Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: A 12-week, randomized, placebo-controlled, Phase 2 study comparing different dose-escalation schemes
Aditi R. Saxena MD, Juan P. Frias MD, Donal N. Gorman PhD, Rene N. Lopez MPH, Nabil Andrawis MD, Nikolaos Tsamandouras PhD, Morris J. Birnbaum MD,Â
doi : 10.1111/dom.15168
Respiratory effort during sleep and the rate of prevalent type 2 diabetes in obstructive sleep apnoea
Jean-Benoit Martinot MD, Nhat-Nam Le-Dong MD, Anne-Laure Borel MD, Renaud Tamisier MD, Atul Malhotra MD, Jean-Louis Pépin MD,Â
doi : 10.1111/dom.15169
Severe hypoglycaemia in adults presenting to a hospital emergency department: Clinical characteristics, comorbidities, and mortality outcomes
Soon H. Song MD, Brian M. Frier MD,Â
doi : 10.1111/dom.15170
Trajectories of fasting glucose and glycated haemoglobin in obese and non-obese incident diabetes: Results from two large cohort studies
Hong-Jie Yu MSc, Mandy Ho PhD, Pui Hing Chau PhD, Daniel Yee Tak Fong PhD,Â
doi : 10.1111/dom.15173
Neighbourhood-level social deprivation and the risk of recurrent heart failure hospitalizations in type 2 diabetes
Salil V. Deo MD, Sadeer Al-Kindi MD, Issam Motairek MD, Yakov E. Elgudin MD, Eiran Gorodeski MD, Khurram Nasir MD, Sanjay Rajagopalan MD, Mark C. Petrie MD, Naveed Sattar MD,Â
doi : 10.1111/dom.15174
Nutritional strategies for correcting low glucose values in patients with postbariatric hypoglycaemia: A randomized controlled three-arm crossover trial
Katja A. Schönenberger MSc, Antonio Ferreira MD, Céline Stebler BSc, Francesco Prendin PhD, Joanna Gawinecka PhD, Christos T. Nakas PhD, Stefan Mühlebach PharmD, Zeno Stanga MD, Andrea Facchinetti PhD, David Herzig PhD, Lia Bally MD,Â
doi : 10.1111/dom.15175
A prediction model on incident chronic kidney disease among individuals with type 2 diabetes in the United States
Yilu Lin PhD, Hui Shao PhD, Vivian Fonseca MD, Amanda H. Anderson PhD, Vecihi Batuman MD, Lizheng Shi PhD,Â
doi : 10.1111/dom.15177
Evaluating the clinical effectiveness and safety of insulin glargine 300 U/mL in individuals with type 2 diabetes uncontrolled on basal insulin: A real-world evidence study from Saudi Arabia (EVOLUTION)
Faisal Al Malki, Bandar El Damanhoury MD, Abdallah Othman, Zain Alghamdi, Majed AlQahtani, Amr Madgy, Zahir Chouikrat,Â
doi : 10.1111/dom.15178
Diabetes remission in drug-naïve patients with type 2 diabetes after dorzagliatin treatment: A prospective cohort study
Jiao'e Zeng MD, Shenglian Gan MMed, Nianrong Mi MMed, Yunfeng Liu MD, Xiaofei Su MD, Wenli Zhang MMed, Juan Zhang MMed, Fang Yu MMed, Xiaolin Dong MD, Minmin Han MMed, Jianfeng Luo PhD, Yi Zhang MD, Li Chen PhD, Jianhua Ma MD,Â
doi : 10.1111/dom.15179
The effects of empagliflozin on measured glomerular filtration rate and estimated extracellular and plasma volumes in patients with type 2 diabetes
Mikkel Jürgens MD, Morten Schou MD, Philip Hasbak MD, Andreas Kjær MD, Emil Wolsk MD, Bo Zerahn MD, Niels H. Brandt-Jacobsen MD, Peter Gæde MD, Peter Rossing MD, Jens Faber MD, Silvio E. Inzucchi MD, Finn Gustafsson MD, Caroline Kistorp MD,Â
doi : 10.1111/dom.15183
All-cause mortality and cardiovascular outcomes with sodium-glucose Co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes
David R. Riley MBBS, Hani Essa MRes, Philip Austin MRes, Frank Preston MBBS, Isatu Kargbo MA, Gema Hernández Ibarburu MSc, Ramandeep Ghuman MPharm, Daniel J. Cuthbertson PhD, Gregory Y. H. Lip MD, Uazman Alam PhD,Â
doi : 10.1111/dom.15185
Development and validation of a real-world model to predict 1-year Level 3 (severe) hypoglycaemia risk in adults with diabetes (the iNPHORM study, United States)
Alexandria A. Ratzki-Leewing PhD, Jason E. Black MSc, Bridget L. Ryan PhD, Guangyong Zou PhD, Neil Klar PhD, Susan Webster-Bogaert MA, Kristina Timcevska BMSc, Stewart B. Harris CM,Â
doi : 10.1111/dom.15186
Combining polygenic risk scores and human leukocyte antigen variants for personalized risk assessment of type 1 diabetes in the Taiwanese population
Wen-Ling Liao, Yu-Nan Huang PhD, Ya-Wen Chang MS, Ting-Yuan Liu PhD, Hsing-Fang Lu PhD, Zih-Yu Tiao, Pen-Hua Su PhD, Chung-Hsing Wang MD, Fuu-Jen Tsai PhD,Â
doi : 10.1111/dom.15187
Association of socioeconomic deprivation with sleep health in patients with type 2 diabetes
Pei Xue PhD, Xiao Tan PhD, Christian Benedict PhD,Â
doi : 10.1111/dom.15190
Mediators between canagliflozin and renoprotection vary depending on patient characteristics: Insights from the CREDENCE trial
Yohei Doi MD, Takayuki Hamano MD, Satoshi Yamaguchi MD, Yusuke Sakaguchi MD, Jun-Ya Kaimori MD, Yoshitaka Isaka MD,Â
doi : 10.1111/dom.15191
Bexagliflozin as an adjunct to metformin for the treatment of type 2 diabetes in adults: A 24-week, randomized, double-blind, placebo-controlled trial
Yuan-Di Halvorsen PhD, Annie L. Conery PhD, John Paul Lock MD, Wenjiong Zhou PhD, Mason W. Freeman MD,Â
doi : 10.1111/dom.15192
Safety of sodium-glucose cotransporter 2 inhibitors in elderly patients with type 2 diabetes: A meta-analysis of randomized controlled trials
Mauro Rigato MD, Gian Paolo Fadini MD, Angelo Avogaro MD,Â
doi : 10.1111/dom.15193
Prescription of guideline-directed medical therapies in patients with diabetes and chronic kidney disease from the CURE-CKD Registry, 2019-2020
Susanne B. Nicholas PhD, Kenn B. Daratha PhD, Radica Z. Alicic MD, Cami R. Jones PhD, Lindsey M. Kornowske MS, Joshua J. Neumiller PharmD, Samuel T. Fatoba PhD, Sheldon X. Kong PhD, Rakesh Singh PhD, Keith C. Norris PhD, Katherine R. Tuttle MD,Â
doi : 10.1111/dom.15194
Contemporary trends in the utilization of second-line pharmacological therapies for type 2 diabetes in the United States and the United Kingdom
Devin Abrahami PhD, Elvira D'Andrea MD, Hui Yin MSc, Seoyoung C. Kim MD, Julie M. Paik MD, Deborah Wexler MD, Laurent Azoulay PhD, Elisabetta Patorno MD,Â
doi : 10.1111/dom.15196
The impact of obesity on cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes treated with finerenone: Post hoc analysis of the FIDELITY study
Peter Rossing MD, Stefan D. Anker MD, Gerasimos Filippatos MD, Bertram Pitt MD, Luis M. Ruilope MD, Liana K. Billings MD, Jennifer B. Green MD, Daisuke Koya MD, Ofri Mosenzon MD, Kevin M. Pantalone DO, Christiane Ahlers PhD, Andrea Lage MD, Robert Lawatscheck MD, Andrea Scalise MD, George L. Bakris MD,Â
doi : 10.1111/dom.15197
Incidence of atrial and ventricular arrhythmias in obese patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan
Mohammad Abumayyaleh MD, Jonathan Demmer MD, Carina Krack MD, Christina Pilsinger MD, Ibrahim El-Battrawy MD, Assem Aweimer MD, Siegfried Lang MD, Andreas Mügge MD, Ibrahim Akin MD,Â
doi : 10.1111/dom.15198
Variants within the LPL gene confer susceptility to diabetic kidney disease and rapid decline in kidney function in Chinese patients with type 2 diabetes
Yu Wu MD, Si Cheng MD, Hongqiu Gu PhD, Kaixuan Yang PhD, Zhe Xu PhD, Xia Meng MD, Yilong Wang MD, Yong Jiang PhD, Hao Li PhD, Yilun Zhou MD, Yongjun Wang MD,Â
doi : 10.1111/dom.15199
Effects of sodium-glucose co-transporter-2 inhibitors by background cardiovascular medications: A systematic review and meta-analysis
Ioannis Avgerinos MD, Thomas Karagiannis MD, David R. Matthews MD, Apostolos Tsapas MD, Eleni Bekiari MD,Â
doi : 10.1111/dom.15200
Cost-effectiveness of canagliflozin and dapagliflozin for treatment of patients with chronic kidney disease and type 2 diabetes
Bao-Ngoc Nguyen PharmD, Shweta Mital PhD, Shawn Bugden PharmD, Hai V. Nguyen PhD,Â
doi : 10.1111/dom.15201
Oral anticoagulation across diabetic subtypes in patients with newly diagnosed atrial fibrillation: A report from the GARFIELD-AF registry
Jean-Pierre Bassand MD, Saverio Virdone MSc, A. John Camm MD, Keith A. A. Fox MBChB, Samuel Z. Goldhaber MD, Shinya Goto MD, Sylvia Haas MD, Werner Hacke MD, Gloria Kayani BSc, Matyas Keltai MD, Frank Misselwitz MD, Karen S. Pieper MS, Alexander G. G. Turpie MD, Freek W. A. Verheugt MD, Ajay K. Kakkar MBBS, for the GARFIELD-AF Investigators ,Â
doi : 10.1111/dom.15202
Risk of hospitalization with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes lacking evidence of chronic kidney disease: Real-world data
Meir Schechter MD, Cheli Melzer Cohen MSc, Tamir Zelter MD, Ilan Yanuv MSc, Aliza Rozenberg MA, Gabriel Chodick PhD, Avraham Karasik MD, Ofri Mosenzon MD,Â
doi : 10.1111/dom.15172
Sumatriptan, a serotonin 5HT1B receptor agonist, acutely reduces insulin secretion and sensitivity and glucose effectiveness in overweight humans: A double-blinded placebo-controlled cross-over trial
Rajna Golubic MD, Mouhamad Hussein Ismail MB BCh, Masa Josipovic MD, Jane Kennet RN, Alfonso Galderisi MD, Mark L. Evans MD,Â
doi : 10.1111/dom.15176
Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes: An exploratory, randomized, open-label, crossover trial
Jens Christian Laursen MD, Viktor Rotbain Curovic MD, Marjolein Y. A. M. Kroonen PhD, Niels Jongs PhD, Emilie H. Zobel MD, Tine W. Hansen PhD, Marie Frimodt-Møller PhD, Gozewijn D. Laverman MD, Adriaan Kooy MD, Frederik Persson DMSc, Hiddo J. L. Heerspink PhD, Christian Stevns Hansen PhD, Peter Rossing DMSc,Â
doi : 10.1111/dom.15180
An update on the incidence of type 1 diabetes during the COVID-19 pandemic years
Carlo Bruno Giorda MD, Roberto Gnavi MD, Barbara Tartaglino PhD, Lucia Favella PhD, Francesco Romeo MD, Alessandro Migliardi PhD, Silvia Ferro MD, Ivana Rabbone PhD,Â
doi : 10.1111/dom.15182
Urinary α1 microglobulin level is useful for selecting sodium-glucose transporter 2 inhibitor or metformin for visceral fat reduction in patients with type 2 diabetes
Masaya Koshizaka MD, Ryoichi Ishibashi MD, Ko Ishikawa MD, Mayumi Shoji MD, Kana Ide MD, Shintaro Ide MD, Hisaya Kato MD, Naoya Teramoto MD, Ryo Terayama MD, Yoshiro Maezawa MD, Koutaro Yokote MD, PRIME-V Study Group ,Â
doi : 10.1111/dom.15188
